PL2344539T3 - Leczenie pediatrycznej ostrej białaczki limfoblastycznej - Google Patents
Leczenie pediatrycznej ostrej białaczki limfoblastycznejInfo
- Publication number
- PL2344539T3 PL2344539T3 PL09764710T PL09764710T PL2344539T3 PL 2344539 T3 PL2344539 T3 PL 2344539T3 PL 09764710 T PL09764710 T PL 09764710T PL 09764710 T PL09764710 T PL 09764710T PL 2344539 T3 PL2344539 T3 PL 2344539T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- lymphoblastic leukemia
- acute lymphoblastic
- pediatric acute
- pediatric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US22126909P | 2009-06-29 | 2009-06-29 | |
| EP09764710.1A EP2344539B1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
| PCT/EP2009/007969 WO2010052013A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2344539T3 true PL2344539T3 (pl) | 2015-07-31 |
Family
ID=41796119
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09764710T PL2344539T3 (pl) | 2008-11-07 | 2009-11-06 | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
| PL17206868T PL3330293T3 (pl) | 2008-11-07 | 2009-11-06 | Leczenie ostrej białaczki limfoblastycznej wieku dziecięcego za pomocą biswoistych przeciwciał przeciwko cd3xcd19 |
| PL15154416T PL2918604T3 (pl) | 2008-11-07 | 2009-11-06 | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17206868T PL3330293T3 (pl) | 2008-11-07 | 2009-11-06 | Leczenie ostrej białaczki limfoblastycznej wieku dziecięcego za pomocą biswoistych przeciwciał przeciwko cd3xcd19 |
| PL15154416T PL2918604T3 (pl) | 2008-11-07 | 2009-11-06 | Leczenie pediatrycznej ostrej białaczki limfoblastycznej |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20110262440A1 (pl) |
| EP (4) | EP2344539B1 (pl) |
| JP (2) | JP5798036B2 (pl) |
| KR (1) | KR101695329B1 (pl) |
| CN (2) | CN102209729B (pl) |
| AU (1) | AU2009313039B2 (pl) |
| BR (1) | BRPI0921341A2 (pl) |
| CA (1) | CA2742242C (pl) |
| CY (3) | CY1116160T1 (pl) |
| DK (3) | DK2344539T3 (pl) |
| ES (3) | ES2662929T3 (pl) |
| HK (1) | HK1255590B (pl) |
| HR (3) | HRP20150400T1 (pl) |
| HU (3) | HUE036922T2 (pl) |
| IL (1) | IL212651A (pl) |
| LT (2) | LT3330293T (pl) |
| MX (1) | MX2011002931A (pl) |
| NO (1) | NO2918604T3 (pl) |
| NZ (1) | NZ591312A (pl) |
| PL (3) | PL2344539T3 (pl) |
| PT (3) | PT2344539E (pl) |
| RS (3) | RS53980B1 (pl) |
| RU (3) | RU2536933C2 (pl) |
| SG (1) | SG195549A1 (pl) |
| SI (3) | SI3330293T1 (pl) |
| SM (3) | SMT201800149T1 (pl) |
| WO (1) | WO2010052013A1 (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| CN102209729B (zh) * | 2008-11-07 | 2016-05-25 | 安进研发（慕尼黑）股份有限公司 | 小儿急性淋巴细胞白血病的治疗方法 |
| ES2565439T3 (es) * | 2009-01-09 | 2016-04-04 | Oxford Biomedica (Uk) Ltd | Factores |
| US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| NZ746691A (en) | 2012-11-13 | 2020-08-28 | Astellas Pharma Inc | Agents for treatment of claudin expressing cancer diseases |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN103131777A (zh) * | 2013-02-05 | 2013-06-05 | 南京艾迪康医学检验所有限公司 | 用于检测e2a-pbx融合基因相对表达量的试剂盒 |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| LT3149480T (lt) | 2014-05-30 | 2019-04-25 | Amgen Research (Munich) Gmbh | B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas |
| US20170252364A1 (en) | 2014-07-30 | 2017-09-07 | Mor Research Applications Ltd. | Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof |
| WO2016061368A1 (en) * | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| AU2015350075B2 (en) | 2014-11-17 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using CD3xCD20 bispecific antibody |
| EP3253408A4 (en) * | 2015-02-05 | 2018-09-26 | Stc.Unm | Anti-pre-bcr antagonists and methods |
| US10556952B2 (en) | 2015-03-30 | 2020-02-11 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to Fc gamma receptors |
| IL303972A (en) | 2015-04-08 | 2023-08-01 | Novartis Ag | CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell |
| DK3298042T3 (da) | 2015-05-20 | 2025-02-24 | Amgen Res Munich Gmbh | B-celledepletering som en diagnostisk markør |
| TWI784917B (zh) | 2015-09-23 | 2022-11-21 | 美商再生元醫藥公司 | 最優化抗ｃｄ３雙特異性抗體及其用途 |
| EA201891495A1 (ru) * | 2015-12-22 | 2018-11-30 | Ридженерон Фармасьютикалз, Инк. | Биспецифические анти-cd20/анти-cd3 антитела для лечения острого лимфобластного лейкоза |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| CA3017743A1 (en) * | 2016-03-14 | 2017-09-21 | Millennium Pharmaceuticals, Inc. | Method of preventing graft versus host disease |
| KR20240036704A (ko) * | 2016-06-06 | 2024-03-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 이용한 b 세포 악성종양의 치료 방법 |
| EP3548046A2 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors |
| AU2018261951B2 (en) * | 2017-05-05 | 2025-05-22 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| IL280875B2 (en) | 2018-08-31 | 2024-12-01 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
| JP7680358B2 (ja) * | 2019-01-30 | 2025-05-20 | ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー | 癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
| EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US12285494B2 (en) | 2021-02-16 | 2025-04-29 | Children's Health Care | Methods for treating B-ALL by administering a pre-BCR complex antagonist |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| PE20241619A1 (es) | 2021-10-15 | 2024-08-07 | Amgen Res Munich Gmbh | Administracion subcutanea de anticuerpos acopladores a linfocitos t de union a cd19 |
| WO2025101672A1 (en) | 2023-11-06 | 2025-05-15 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| US20250230251A1 (en) | 2023-12-20 | 2025-07-17 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rb) and related methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4119397A (en) * | 1996-08-28 | 1998-03-19 | Viva Diagnostika Diagnostische Produkte Gmbh | Novel combination preparations and their use in immunodiagnosis and immunotherapy |
| DK1071752T3 (da) * | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
| JP2008501621A (ja) * | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| JP4948174B2 (ja) * | 2003-10-16 | 2012-06-06 | マイクロメット アクツィエン ゲゼルシャフト | 多重特異的脱免疫ｃｄ３−結合物質 |
| US8007796B2 (en) | 2005-12-16 | 2011-08-30 | Micromet Ag | Means and methods for the treatment of tumorous diseases |
| JP5825756B2 (ja) * | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2009299793B2 (en) * | 2008-10-01 | 2016-03-10 | Amgen Research (Munich) Gmbh | Bispecific single chain antibodies with specificity for high molecular weight target antigens |
| CN102209729B (zh) * | 2008-11-07 | 2016-05-25 | 安进研发（慕尼黑）股份有限公司 | 小儿急性淋巴细胞白血病的治疗方法 |
| CN102282128B (zh) * | 2009-01-19 | 2015-06-17 | Abbvie公司 | 用于治疗癌症和免疫和自身免疫疾病的细胞程序死亡诱导药剂 |
| HUE025527T2 (en) * | 2009-01-19 | 2016-04-28 | Abbvie Inc | Apoptosis inducers for the treatment of cancer, immune and autoimmune diseases |
| JP2012528177A (ja) * | 2009-05-27 | 2012-11-12 | アボット・ラボラトリーズ | キナーゼ活性のピリミジン阻害剤 |
| CN105820138A (zh) * | 2009-09-20 | 2016-08-03 | Abbvie 公司 | 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物 |
| NZ598732A (en) * | 2009-10-27 | 2014-09-26 | Amgen Res Munich Gmbh | Dosage regimen for administering a cd19xcd3 bispecific antibody |
-
2009
- 2009-11-06 CN CN200980144400.7A patent/CN102209729B/zh active Active
- 2009-11-06 SM SM20180149T patent/SMT201800149T1/it unknown
- 2009-11-06 PL PL09764710T patent/PL2344539T3/pl unknown
- 2009-11-06 EP EP09764710.1A patent/EP2344539B1/en active Active
- 2009-11-06 RS RS20150306A patent/RS53980B1/sr unknown
- 2009-11-06 EP EP15154416.0A patent/EP2918604B1/en active Active
- 2009-11-06 SM SM20190546T patent/SMT201900546T1/it unknown
- 2009-11-06 SI SI200931995T patent/SI3330293T1/sl unknown
- 2009-11-06 CA CA2742242A patent/CA2742242C/en active Active
- 2009-11-06 HU HUE15154416A patent/HUE036922T2/hu unknown
- 2009-11-06 EP EP17206868.6A patent/EP3330293B1/en active Active
- 2009-11-06 HU HUE17206868A patent/HUE046222T2/hu unknown
- 2009-11-06 PT PT97647101T patent/PT2344539E/pt unknown
- 2009-11-06 LT LTEP17206868.6T patent/LT3330293T/lt unknown
- 2009-11-06 US US13/127,538 patent/US20110262440A1/en not_active Abandoned
- 2009-11-06 RU RU2011122827/10A patent/RU2536933C2/ru active
- 2009-11-06 PT PT172068686T patent/PT3330293T/pt unknown
- 2009-11-06 KR KR1020117010642A patent/KR101695329B1/ko active Active
- 2009-11-06 JP JP2011533632A patent/JP5798036B2/ja active Active
- 2009-11-06 PL PL17206868T patent/PL3330293T3/pl unknown
- 2009-11-06 MX MX2011002931A patent/MX2011002931A/es active IP Right Grant
- 2009-11-06 LT LTEP15154416.0T patent/LT2918604T/lt unknown
- 2009-11-06 CN CN201610281293.4A patent/CN106390114A/zh active Pending
- 2009-11-06 BR BRPI0921341A patent/BRPI0921341A2/pt not_active Application Discontinuation
- 2009-11-06 SI SI200931185T patent/SI2344539T1/sl unknown
- 2009-11-06 ES ES15154416.0T patent/ES2662929T3/es active Active
- 2009-11-06 RS RS20180309A patent/RS56989B1/sr unknown
- 2009-11-06 NO NO15154416A patent/NO2918604T3/no unknown
- 2009-11-06 RS RSP20191232 patent/RS59348B1/sr unknown
- 2009-11-06 WO PCT/EP2009/007969 patent/WO2010052013A1/en not_active Ceased
- 2009-11-06 ES ES17206868T patent/ES2748126T3/es active Active
- 2009-11-06 ES ES09764710.1T patent/ES2535257T3/es active Active
- 2009-11-06 HU HUE09764710A patent/HUE025452T2/en unknown
- 2009-11-06 DK DK09764710.1T patent/DK2344539T3/en active
- 2009-11-06 AU AU2009313039A patent/AU2009313039B2/en active Active
- 2009-11-06 SI SI200931817T patent/SI2918604T1/en unknown
- 2009-11-06 EP EP19187179.7A patent/EP3594237A1/en active Pending
- 2009-11-06 SG SG2013076310A patent/SG195549A1/en unknown
- 2009-11-06 DK DK17206868.6T patent/DK3330293T3/da active
- 2009-11-06 HR HRP20150400TT patent/HRP20150400T1/hr unknown
- 2009-11-06 NZ NZ591312A patent/NZ591312A/xx unknown
- 2009-11-06 DK DK15154416.0T patent/DK2918604T3/en active
- 2009-11-06 PL PL15154416T patent/PL2918604T3/pl unknown
- 2009-11-06 PT PT151544160T patent/PT2918604T/pt unknown
-
2011
- 2011-05-03 IL IL212651A patent/IL212651A/en active IP Right Grant
-
2014
- 2014-10-13 RU RU2014141180A patent/RU2677324C2/ru active
-
2015
- 2015-03-31 CY CY20151100317T patent/CY1116160T1/el unknown
- 2015-04-27 SM SM201500104T patent/SMT201500104B/xx unknown
- 2015-08-20 JP JP2015163116A patent/JP6130451B2/ja active Active
-
2018
- 2018-03-12 HR HRP20180426TT patent/HRP20180426T1/hr unknown
- 2018-03-14 CY CY20181100310T patent/CY1120022T1/el unknown
- 2018-11-16 HK HK18114719.1A patent/HK1255590B/en unknown
- 2018-12-14 RU RU2018144313A patent/RU2736802C2/ru active
-
2019
- 2019-09-20 HR HRP20191715 patent/HRP20191715T1/hr unknown
- 2019-10-03 CY CY20191101035T patent/CY1122428T1/el unknown
-
2022
- 2022-09-16 US US17/932,739 patent/US20230235053A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL212651A0 (en) | Treatment of pediatric acute lymphoblastic leukemia | |
| AU2018260815A1 (en) | Treatment of Acute Lymphoblastic Leukemia | |
| IL248204A0 (en) | Combined treatment of tumors expressing 38cd | |
| ZA201006648B (en) | Methods of treatment | |
| NO2016023I1 (no) | Glycerol fenylbutyrat | |
| EP2049139A4 (en) | TREATMENT OF TUMORS EXPRESSING RAS | |
| HRP20181877T1 (hr) | Postupci za liječenje lijekovima koji uklanjaju amonijak | |
| EP2164494A4 (en) | Methods of Treatment | |
| GB0723100D0 (en) | Treatment of HFnEF | |
| EP2124950A4 (en) | PAIN TREATMENT WITH NALOXONE | |
| ZA200807306B (en) | Treatment of acute respiratory distress syndrome | |
| GB0814043D0 (en) | The treatment of skin disorders | |
| GB0700969D0 (en) | Methods of treatment | |
| GB0720136D0 (en) | Treatment of blood disorded | |
| GB0809319D0 (en) | The treatment of puritus | |
| IL192121A0 (en) | Treatment of acute respiratory distress syndrdme | |
| GB0625602D0 (en) | Treatment of sialorrhoea | |
| GB0700886D0 (en) | Medical treatment | |
| SI2330892T1 (sl) | Postopki zdravljenja z uporabo zdravil, ki odstranjujejo amoniak | |
| GB0704989D0 (en) | Treatment of influenza | |
| GB0820562D0 (en) | Novel use and treatment |